Overview

Febuxostat Versus Allopurinol Control Trial in Subjects With Gout

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Allopurinol
Febuxostat